Sunitinib in hepatocellular carcinoma: redefining appropriate dosing, schedule, and activity end points.
Faivre
Sandrine J
SJ
Bouattour
Mohamed
M
Dreyer
Chantal
C
Raymond
Eric
E
D020533:Angiogenesis Inhibitors / Q000008:administration & dosage* / Q000009:adverse effects; D006528:Carcinoma, Hepatocellular / Q000098:blood supply / Q000000981:diagnostic imaging / Q000188:drug therapy*; D017326:Clinical Trials, Phase III as Topic; D018572:Disease-Free Survival; D004305:Dose-Response Relationship, Drug; D004334:Drug Administration Schedule; D023381:Endpoint Determination; D006801:Humans; D007211:Indoles / Q000008:administration & dosage* / Q000009:adverse effects; D008113:Liver Neoplasms / Q000098:blood supply / Q000000981:diagnostic imaging / Q000188:drug therapy*; D011758:Pyrroles / Q000008:administration & dosage* / Q000009:adverse effects; D000077210:Sunitinib; D013997:Time Factors; D014057:Tomography, X-Ray Computed; D016896:Treatment Outcome
D020533:Angiogenesis Inhibitors; D007211:Indoles; D011758:Pyrroles; D000077210:Sunitinib